For Researchers
October 16, 2025

If You’re Attending CNS Summit for the First Time

Our team has attended CNS for years. It’s one of the most intellectually rich, surprising, and community-forward events in the industry. If you’re new, here’s how to make the most of it:

Our team has attended CNS for years. It’s one of the most intellectually rich, surprising, and community-forward events in the industry. If you’re new, here’s how to make the most of it:

🥂 Go to every reception.

Seriously. This is where biotech CMOs talk to neurotech engineers. Where pharma innovation leads meet patient advocates. Where people actually share what they’re stuck on. These informal, high-context conversations are often more valuable than the sessions themselves.

🧠 Spend serious time at the posters.

The CNS poster sessions are where real technical breakthroughs show up first. If you care about how we measure cognition, emotion, behavior, or experience — this is where the good stuff is.
Validated digital endpoints. Passive sensing. EMA protocols. It’s the highest signal-to-noise ratio you’ll find at a conference this size.

🎭 Go to the party — and commit to the theme.

Whatever the theme is this year, lean in. Trust us: the best conversations don’t happen in your conference badge; they happen in glitter, faux furs, or LED headgear. This is science with a soul.

🤝 Offer to help.

The industry is in flux. Budgets are tighter. People are reevaluating priorities.
Come in with curiosity and generosity. Ask smart questions. Make a useful intro. Co-write a pilot. CNS isn’t just about innovation — it’s about collaboration.

What We’re Thinking About — and Talking About on Stage

1. What do DCTs actually look like now?

After a decade of hype, a global pandemic, and a necessary reset, where do decentralized trials really fit? We’re seeing the dust settle — and a much clearer picture emerge of how to integrate DCTs in practical, credible, and capital-efficient ways.

Catch our Innovation Showcase on the main stage — we’re going deep on what DCTs look like in 2025 (and what they don’t).

2. How do we preserve temporal rigor in decentralized trials?

When people don’t come into a clinic, time becomes your central organizing principle. We’ve spent years building participant journeys that mirror traditional study rigor — but adapt to the real lives and schedules of people at home.

We think about everything from:

3. Which endpoints actually translate?

We’re especially interested in:

Our goal: Help researchers collect real-world endpoints that still meet regulatory standards.

4. How do we empower researchers across backgrounds?

Alethios isn’t just built for CROs and pharma sponsors. It’s also for researchers in emerging fields, citizen scientists, and underfunded areas that need credibility to grow. We support research on everything from endometriosis to neuroenhancement, menopause to metabolism — and we do it with infrastructure that makes study management, adherence, and automation actually scalable.

5. Will capital efficiency become center stage?

We think so.
The smartest teams aren’t just talking about speed anymore — they’re talking about derisking. Running well-powered, lower-cost, decentralized studies before going big. Using real-world endpoints to prequalify concepts. Making smarter bets.

Where Alethios Fits In

We’ve built a platform that helps researchers run real-world trials with:

It’s comprehensive research infrastructure — not cobbled-together point solutions.
We make it easier to design once, launch quickly, and learn clearly.

We’ll see you at CNS — at the posters, on stage, and in the conversations that move our field forward..

More Blog Posts

View All Posts
Take the next step

Be Part of the Future of Health Research

Whether you're a researcher or participant, Alethios makes health research effortless and impactful.